Key statistics
On Friday, Dyne Therapeutics Inc (DYN:NSQ) closed at 15.62, 145.60% above the 52 week low of 6.36 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 15.72 |
|---|---|
| High | 16.01 |
| Low | 15.10 |
| Bid | 14.96 |
| Offer | 15.10 |
| Previous close | 16.19 |
| Average volume | 1.86m |
|---|---|
| Shares outstanding | 161.59m |
| Free float | 156.93m |
| P/E (TTM) | -- |
| Market cap | 2.52bn USD |
| EPS (TTM) | -3.66 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
More ▼
- Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
- Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
- Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
- Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
- Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
More ▼
